recordId int64 | PMID int64 | title string | abstract string | labels int64 | abstract_labels int64 |
|---|---|---|---|---|---|
4,136 | 9,403,280 | Drug-induced chest pain and myocardial infarction. Reports to a national centre and review of the literature. | OBJECTIVES: To analyse reports of drug-induced myocardial infarction and chest pain sent to a national reporting centre. To review which drugs were suspected of exhibiting these adverse events and what mechanisms were involved. METHODS: During the 20-year period 1975 through 1994, a total of 19,141 reports on adverse ... | 0 | 1 |
5,455 | 12,199,263 | Selegiline: a second look. Six years later: too risky in Parkinson's disease. | (1) The reference treatment for Parkinson's disease is levodopa plus a peripheral dopadecarboxylase inhibitor (benserazide or carbidopa). (2) In 1996, selegiline, a type B MAOI marketed in France since 1988, saw its indications extended to cover single-agent therapy of early-stage Parkinson's disease, and in combinatio... | 0 | 0 |
6,160 | 8,730,971 | Comparison of the effects of clonidine on tyramine- and methoxamine-evoked mydriasis in man. | 1. It has been reported previously that clonidine can potentiate tyramine-evoked mydriasis on the pain-free side of cluster headache patients. We examined whether a single oral dose of clonidine (200 micrograms) can also potentiate tyramine-evoked mydriasis in healthy subjects, using mydriasis to methoxamine, a directl... | 0 | 0 |
7,357 | 12,371,307 | New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials? | OBJECTIVE: To determine how many randomized controlled trials on the safety or efficacy of new drugs are published when these drugs are first marketed in Canada, and to determine the quality of the information in those trials. DESIGN: A MEDLINE search was conducted on each drug identified as having novel therapeutic c... | 0 | 0 |
7,453 | 12,682,669 | The year's new drugs. | The United States was the most active market for new product launches (22 products, 62.5%) in a year that saw 35 new chemical entities and biological drugs and two diagnostic agents reach their first markets. The most active therapeutic groups were anti-infective, oncolytic and metabolic drugs with five launches for ea... | 0 | 0 |
7,928 | 10,427,351 | Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. | The efficacy of 5-hydroxytryptamine 1B/1D (5-HT 1B/1D) agonists is related to their inhibitory effects on neurogenic inflammation, mediated through serotoninergic control mechanisms. Recently, a series of oral second generation 5-HT 1B/1D agonists (eletriptan, naratriptan, rizatriptan and zolmitriptan) have been develo... | 0 | 0 |
7,968 | 10,524,661 | Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study. | Polypharmacy (the prescription of more than one therapy for a single patient) and subcutaneous (s.c.) sumatriptan tolerability were prospectively studied in 12,339 migraineurs, each followed for up to 1 year. Inclusion/exclusion criteria were minimal and mirrored United States Imitrex labeling. Drug usage and complianc... | 0 | 0 |
7,972 | 10,524,662 | Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. | In a multicenter study, a long-term analysis was made of the efficacy, safety, and tolerability of subcutaneous (s.c.) sumatriptan in the acute treatment of migraine attacks over a period of up to 18 months. A total of 2263 patients took part in the study, all able to perform their own acute treatment of migraine attac... | 0 | 1 |
8,010 | 10,631,628 | Lack of pharmacokinetic interaction between sumatriptan and naproxen. | Sumatriptan is a 5HT1D agonist used in the treatment of migraine. Nonsteroidal anti-inflammatory drugs, beta-blockers, and calcium channel-blocking antagonists are used in the prophylaxis of migraine. Hence, there is a need to investigate the interaction of these prophylactic drugs with sumatriptan. The interaction of ... | 0 | 0 |
8,147 | 10,891,904 | Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. | BACKGROUND: Autoantibodies to glutamic acid decarboxylase (GAD-A) are present in type 1 diabetes and stiff man syndrome (SMS), and have also been reported in cerebellar ataxia. Epilepsy was present in 4 of 19 patients with SMS and GAD-A, implying that epilepsy sometimes is associated with anti-GAD autoimmunity. METHOD... | 0 | 0 |
8,352 | 11,252,291 | A systematic review of the use of triptans in acute migraine. | OBJECTIVE: A systematic review of the literature was undertaken, to consolidate evidence concerning the efficacy and safety of triptans currently available in Canada (sumatriptan, rizatriptan, naratriptan, zolmitriptan), and to provide guidelines for selection of a triptan. METHODS: Data from published, randomized, pl... | 0 | 1 |
8,381 | 11,292,228 | Preventive therapy in pediatric migraine. | Preventive therapy for migraine headache includes identification of migraine precipitants, possible adjustments in lifestyle, appropriate management of acute headache, and, when necessary, the use of pharmacologic agents. There are no well-controlled clinical trials with sufficient patient numbers to support the use of... | 0 | 0 |
8,388 | 11,298,665 | Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. | This study was designed to assess the pharmacokinetics of almotriptan, a 5-HT1B/1D agonist, when administered in the presence and absence of propranolol. Healthy male (n = 10) and female (n = 2) volunteers received (i) 80 mg propranolol twice daily for 7 days and 12.5 mg almotriptan on day 7, and (ii) 12.5 mg almotript... | 0 | 0 |
8,452 | 11,453,892 | Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. | AIMS: Patients with migraine may receive the 5-HT1B/1D agonist, rizatriptan (5 or 10 mg), to control acute attacks. Patients with frequent attacks may also receive propranolol or other beta-adrenoceptor antagonists for migraine prophylaxis. The present studies investigated the potential for pharmacokinetic or pharmaco... | 0 | 0 |
8,696 | 12,027,785 | Practical approaches to migraine management. | Migraine is a recurrent clinical syndrome characterised by combinations of neurological, gastrointestinal and autonomic manifestations. The exact pathophysiological disturbances that occur with migraine have yet to be elucidated; however, cervico-trigemino-vascular dysfunctions appear to be the primary cause. Despite a... | 0 | 0 |
8,826 | 12,269,863 | Spotlight on rizatriptan in migraine. | Rizatriptan is an orally active serotonin 5-HT(1) receptor agonist that potently and selectively binds to 5-HT(1B/1D) subtypes. Earlier clinical trials demonstrated that rizatriptan 5 or 10mg is more effective than placebo at providing pain relief and a pain-free state, relieving associated symptoms of migraine, normal... | 0 | 1 |
8,878 | 12,435,222 | Pharmacologic management of acute attacks of migraine and prevention of migraine headache. | null | 0 | 1 |
9,001 | 12,636,467 | Headache assessment and management. | null | 0 | 0 |
9,020 | 12,656,712 | Sumatriptan in migraine with unilateral cranial autonomic symptoms: an open study. | OBJECTIVE: To investigate the response to sumatriptan in migraineurs with unilateral cranial autonomic symptoms such as lacrimation, eye redness, eyelid edema, nasal congestion, and rhinorrhea. BACKGROUND: Given the potential large-scale recruitment of peripheral neurovascular 5-HT1B/1D receptors consequent to the act... | 1 | 1 |
9,042 | 12,674,472 | AAFP/ACP-ASIM release guidelines on the management and prevention of migraines. | null | 0 | 0 |
9,079 | 12,697,002 | The triptan formulations : how to match patients and products. | The 5-HT(1B/1D) receptor agonists (the 'triptans') are migraine-specific agents that have revolutionised the treatment of migraine. They are usually the drugs of choice to treat a migraine attack in progress. Different triptans are available in various strengths and formulations, including oral tablets, orally disinteg... | 0 | 0 |
9,208 | 12,806,521 | The triptan formulations: a critical evaluation. | The migraine-specific triptans have revolutionized the treatment of migraine and are usually the drugs of choice to treat a migraine attack in progress. Different triptans are available in different strengths and formulations including oral tablets, orally disintegrating tablets, nasal sprays and subcutaneous injection... | 0 | 0 |
9,244 | 12,831,340 | A review of the clinical efficacy and tolerability of almotriptan in acute migraine. | Almotriptan is a serotonin (5-hydroxytryptamine, 5HT)(1B/1D)-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consis... | 0 | 0 |
9,265 | 12,858,071 | The evolving management of migraine. | PURPOSE OF REVIEW: To review recent advances in acute and preventive migraine treatment. RECENT FINDINGS: The number of migraine drugs continues to expand, allowing for more flexible and tolerable treatment plans. Two new triptans, frovatriptan and eletriptan, and a nasal formulation of zolmitriptan have been recently... | 0 | 1 |
9,306 | 12,918,889 | Establishing principles for migraine management in primary care. | Published guidelines for the management of migraine in primary care were evaluated by an international advisory board of headache specialists, to establish evidence-based principles of migraine management that could be recommended for international use. Twelve principles of migraine management were identified, covering... | 0 | 0 |
9,366 | 14,562,585 | Cyclic vomiting syndrome: a brain-gut disorder. | Despite the "black box" surrounding CVS, the authors' understanding of this clinical entity has advanced substantially in the last decade as a result of an international interdisciplinary clinical and research effort. Although CVS is now recognized as a unique clinical entity, patients still undergo innumerable hospita... | 0 | 0 |
9,883 | 8,879,897 | Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System. | The efficacy and tolerability of subcutaneous (SC) sumatriptan administered with the IMITREX (sumatriptan succinate) STATdose System, which circumvents the need for patients or health care professionals to handle a syringe, were evaluated in two randomized, double-masked, parallel-group, placebo-controlled, multicenter... | 0 | 1 |
10,107 | 9,403,359 | The way to serotonergic use and abuse in migraine. | 5-HT is currently indicated to play a role in migraine (M). Previously evidenced 5-HT supersensitivity which characterizes M is insufficient to compensate for a possible deficit in 5-HT bioavailability. Inducing a further up-regulation of 5-HT receptor can yield improvement of M syndrome. Chronic treatments of methyser... | 0 | 0 |
10,118 | 9,431,839 | The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). | AIMS: Zolmitriptan (Zomig, formerly known as 311C90), a selective 5HT1B/1D agonist is under development as an acute oral treatment for migraine. Despite the use of prophylactic medication, such as propranolol, breakthrough attacks often occur in patients. Consequently we investigated the effects of propranolol on the ... | 0 | 0 |
10,250 | 9,755,356 | Serotonergic synergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs. | It has become common clinical practice to combine the selective serotonin reuptake inhibitors with other serotonergic agents for augmentation or adjunctive purposes. The empirical basis for using these combinations remains limited, but is growing. Also growing is a literature that suggests that even the most apparently... | 0 | 0 |
10,534 | 11,926,699 | Dipyridamole may be used safely in patients with ischaemic heart disease. | It is thought that up to 50% of patients with cerebrovascular disease will have concurrent ischaemic heart disease. Dipyridamole co-formulated with aspirin has been shown to increase the relative reduction in risk of second stroke in patients with prior stroke/transient ischaemic attack beyond that obtaining with aspir... | 0 | 0 |
10,976 | 8,916,562 | Prescribing practices for the management of headache in Newfoundland and Labrador. | To assess the impact of sumatriptan in clinical practice, we undertook a retrospective analysis of the government of Newfoundland and Labrador's prescription drug program data base for 35 consecutive patients prescribed sumatriptan. The number of doses of all drugs prescribed ranged from 121 to 18,874 on from 4 to 357 ... | 0 | 0 |
11,747 | 11,975,819 | Intraoral chilling versus oral sumatriptan for acute migraine. | Migraine pathophysiology is associated with a dural inflammation. Recent evidence suggests that the primary inflammation occurs in a maxillary nerve segment, accessible intraorally. Local tenderness, related to symptom laterality, has been palpated consistently in asymptomatic migraine patients, and significant migrain... | 0 | 1 |
11,768 | 12,100,094 | Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. | Rizatriptan is an effective and fast acting drug for the acute treatment of migraine. As with any other acute treatment for migraine, headache recurrence may occur in up to one-third of responders. Combination with non-steroidal anti-inflammatory drugs (NSAIDs) seems to reduce the incidence of headache recurrence in cl... | 0 | 0 |
13,468 | 8,721,797 | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | It has been suggested that the quality of clinical trials should be assessed by blinded raters to limit the risk of introducing bias into meta-analyses and systematic reviews, and into the peer-review process. There is very little evidence in the literature to substantiate this. This study describes the development of ... | 0 | 0 |
13,640 | 8,984,084 | Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. | This prospective, open-label study evaluated the effects of subcutaneous sumatriptan versus usual therapy on workplace productivity, activity time outside of work, and health-related quality of life in 43 men or women who were hospital employees diagnosed with migraine according to international Headache Society criter... | 0 | 1 |
14,406 | 11,824,428 | Sibutramine: new preparation. Slight weight loss; but also a slight rise in blood pressure ... | (1) The reference treatment for achieving weight loss by obese patients is a combination of dietary measures, exercise and behavioural interventions. There is currently no drug treatment with demonstrated efficacy on the morbidity or mortality associated with excess body weight. (2) Sibutramine, a serotonin- and noradr... | 0 | 0 |
16,125 | 10,168,039 | A multinational investigation of the impact of subcutaneous sumatriptan. I: Design, methods and clinical findings. | This report describes the design, methods and clinical results of a prospective sequential multinational (5 countries) study conducted to evaluate the effects of subcutaneous sumatriptan on health-related quality of life, workplace productivity, clinical parameters and patient satisfaction. Adult patients with moderate... | 0 | 1 |
16,393 | 11,135,028 | Hypnic headache: another indomethacin-responsive headache syndrome? | Hypnic headache syndrome is a benign, recurrent, late-onset headache disorder that occurs exclusively during sleep. Lithium has been reported to be an effective treatment, but the side effects of this medication are sometimes prohibitive, particularly in the elderly. Other drugs have been reported to be effective in th... | 0 | 0 |
16,397 | 11,145,638 | New avenues in treatment of paediatric migraine: a review of the literature. | BACKGROUND: Headaches are a common problem in paediatric practice. Recurrent headaches can be a significant source of stress for patient and parents, and disruptive regarding school obligations and parental work responsibilities. Most treatment interventions are developed from research data extrapolated from adult stu... | 0 | 1 |
16,459 | 11,379,275 | New generation anti-epileptics for facial pain and headache. | The prophylactic management of recurrent head and facial pains may be challenging because of lack of efficacy and/or bothersome adverse effects of available drug therapies. New generation antiepileptic drugs offer new perspectives in difficult cases. We will review the available published data and present our experienc... | 0 | 0 |
16,542 | 11,595,003 | Drug-resistant cluster headache responding to gabapentin: a pilot study. | Prompted by the results of gabaergic drugs, such as valproate and topiramate, we performed this pilot study to assess the effect of gabapentin in cluster headache. Eight patients suffering from episodic cluster headache and four suffering from chronic cluster headache were studied. All of them had failed to respond to ... | 0 | 0 |
16,597 | 11,807,151 | Migraine--current understanding and treatment. | null | 0 | 0 |
16,674 | 11,990,648 | Chronic tension-type headache: advice for the viselike-headache patient. | About 3% of people experience daily viselike headaches without other associated symptoms, a condition called chronic tension-type headache. Therapy consists of tricyclic antidepressants, biofeedback, and stress management, although compelling data from randomized controlled trials are lacking. | 0 | 0 |
16,723 | 12,105,300 | Neurocognitive sequelae of cancer treatment. | null | 0 | 0 |
16,844 | 12,453,029 | Cost-effectiveness of antiepileptic drugs in migraine prophylaxis. | OBJECTIVE: To analyze the cost-effectiveness of antiepileptics in migraine prophylaxis. METHODS: A cost-effectiveness analysis was performed using efficacy data from three recent, double-blind, placebo-controlled, clinical trials of antiepileptic drugs studied for migraine prevention and cost data. Two measures of cos... | 0 | 0 |
16,891 | 12,525,714 | Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). | OBJECTIVE: To develop a patient-based measure of walking ability in MS. METHODS: Twelve items describing the impact of MS on walking (12-Item MS Walking Scale [MSWS-12]) were generated from 30 patient interviews, expert opinion, and literature review. Preliminary psychometric evaluation (data quality, scaling assumpti... | 0 | 0 |
16,929 | 12,603,635 | Migraine preventive medication reduces resource utilization. | OBJECTIVE: To determine if long-term resource utilization is reduced by adding a preventive medication to a migraine management regimen that already includes acute medication. BACKGROUND: In 2000, new evidence-based guidelines for the treatment of migraine were released by the US Headache Consortium and the American A... | 0 | 0 |
16,933 | 12,603,644 | Effect of autogenic training on drug consumption in patients with primary headache: an 8-month follow-up study. | OBJECTIVE: To examine the effects of Schultz-type autogenic training on headache-related drug consumption and headache frequency in patients with migraine, tension-type, or mixed (migraine plus tension-type) headache over an 8-month period. BACKGROUND: Behavioral treatments often are used alone or adjunctively for dif... | 0 | 0 |
17,064 | 12,858,070 | Update on cluster headache. | PURPOSE OF REVIEW: Although cluster headache has traditionally been thought of as a vascular headache disorder, its periodicity suggests an involvement of central areas such as the hypothalamus. This review covers the past 3 years, which have seen remarkable progress in understanding the pathophysiology of circadian h... | 0 | 0 |
17,220 | 7,721,573 | SUNCT syndrome: trials of drugs and anesthetic blockades. | Nine patients with the SUNCT syndrome (Spanish and Norwegian patients) have, over many years, been given several drugs effective in the cluster headache syndrome, trigeminal neuralgia, and other headaches, as well as drugs not previously used in headache. Various cranial nerves were also anesthetized in an endeavor to ... | 0 | 0 |
17,465 | 8,913,410 | Current developments in neurology, Part I: Advances in the pharmacotherapy of headache, epilepsy, and multiple sclerosis. | When caring for patients with disorders of the central nervous system such as migraine headaches, epilepsy, or MS, clinicians are faced with increasingly complex pharmacotherapeutic options. Pharmacotherapeutic strategies directed toward prevention, reversal, or cure of these diseases are hampered by an incomplete unde... | 0 | 0 |
17,539 | 9,209,777 | Transdermal clonidine in the prophylaxis of episodic cluster headache. | null | 0 | 0 |
17,575 | 9,385,753 | Transdermal clonidine in the prophylaxis of episodic cluster headache: an open study. | Transdermal clonidine has recently been reported to be efficacious in the prophylaxis of cluster headache. A 2-week course of transdermal clonidine (5 mg the first week, 7.5 mg the second week) preceded by a 5-day run-in period, was administered to 16 patients with episodic cluster headache in an active cluster period.... | 0 | 0 |
17,668 | 9,793,699 | Effects of the antimigraine compound zolmitriptan ('Zomig') on psychomotor performance alone and in combination with diazepam in healthy volunteers. | Zolmitriptan (Zomig) is a 5HT1B/1D agonist which has the ability to cross the intact blood-brain barrier to access central as well as peripheral receptors. Because of the potential for central nervous system side effects, this randomized, double-blind, placebo-controlled, 6-period crossover study evaluated the effects ... | 0 | 0 |
17,689 | 9,867,730 | Update in neurology. | null | 0 | 0 |
17,704 | 9,972,386 | Medication-induced headache: overview and systematic review of therapeutic approaches. | OBJECTIVE: To review medication-induced headache (MIH) through a systematic evaluation of the literature regarding the pharmacologic management of this condition. METHODOLOGY: To identify and evaluate all pharmacologic interventions for MIH, we conducted a qualitative systematic review of the English-language literatu... | 0 | 0 |
19,029 | 12,071,780 | Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approach. | The New Zealand Intensive Medicines Monitoring Programme (IMMP) undertakes prospective observational cohort studies on selected new drugs in the early postmarketing period using prescription-event monitoring (PEM) methodology with the purpose of identifying signals of previously unrecognised ADRs and establishing risk ... | 0 | 0 |
19,250 | 12,370,451 | Statins as immunomodulators: comparison with interferon-beta 1b in MS. | BACKGROUND: Recent data suggest that statins may be potent immunomodulatory agents. In order to evaluate the potential role of statins as immunomodulators in MS, the authors studied their immunologic effects in vitro and compared them to interferon (IFN)beta-1b. METHODS: Peripheral blood mononuclear cells (PBMC) obtai... | 0 | 0 |
21,019 | 10,067,807 | Migraine: a "woman's disease?". | Migraine, a chronic disorder characterized by episodes of headache, has a profound effect on the well-being and general functioning of its victims, not only during the acute attacks, but also in terms of impairment of school achievement, work performance, and family/social relationships. Despite staggering social and e... | 0 | 0 |
21,020 | 10,099,854 | Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses. | Menstrual migraine may be debilitating, long-lasting, and refractory to treatment. Because the efficacy and tolerability of abortive and prophylactic treatment options for menstrual migraine have generally not been evaluated in controlled clinical trials, treatment choices are often made on the basis of personal experi... | 0 | 0 |
21,021 | 10,160,470 | Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis. | The annual cost of managing migraine totals billions of US dollars. This retrospective economic analysis of a clinical trial comparing subcutaneous dihydroergotamine mesylate (DHE) with subcutaneous sumatriptan in the treatment of acute migraine is appropriate because, although each product has been shown to be efficac... | 0 | 0 |
21,022 | 10,166,407 | The impact of drug therapy on quality of life in headache and migraine. | Although headache is among the most common and costly disorders in primary care, our understanding of its direct impact on the quality of life of affected individuals is incomplete. While studies evaluating the role of headache on health-related quality of life and healthcare economics are starting to appear in the med... | 0 | 1 |
21,023 | 10,168,035 | Sumatriptan. A pharmacoeconomic review of its use in migraine. | Migraine is a common illness characterised by severe, often throbbing and/or unilateral headache, which may be accompanied by sensitivity to light or noise. A minority of migraine attacks are preceded by transient visual or sensory disturbances. Migraine is associated with reductions in health-related quality of life b... | 0 | 0 |
21,024 | 10,168,040 | A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life. | The aim of this prospective sequential multinational (5 countries) study was to concurrently evaluate the effects of subcutaneous sumatriptan on clinical parameters, health-related quality-of-life (HRQOL) measures, workplace productivity and patient satisfaction. This report presents the HRQOL results. 582 patients (ag... | 0 | 1 |
21,025 | 10,168,041 | A multinational investigation of the impact of subcutaneous sumatriptan. III: Workplace productivity and non-workplace activity. | This report presents the workplace productivity and non-workplace activity results of a multinational study of the effects of subcutaneous sumatriptan 6 mg in the acute treatment of migraine compared with patient's customary therapy. Patients diagnosed with migraine treated their symptoms for 24 weeks with subcutaneous... | 0 | 1 |
21,026 | 10,168,042 | A multinational investigation of the impact of subcutaneous sumatriptan. IV: Patient satisfaction. | This report describes the patient satisfaction results from a prospective, sequential, multinational study. The study was conducted to concurrently evaluate the effects of sumatriptan, compared with customary therapy, on clinical parameters, health-related quality of life, productivity and patient satisfaction in adult... | 0 | 1 |
21,027 | 10,169,243 | Cost-effectiveness of sumatriptan in a managed care population. | We conducted an open-labeled study to determine whether sumatriptan is more cost-effective than other therapies used to treat migraine headache. We contacted by phone 220 sumatriptan users enrolled in QualMed, a health maintenance organization (HMO) in Spokane, Washington. Of these, 203 met the inclusion criteria and 1... | 0 | 1 |
21,028 | 10,179,706 | MSQ: Migraine-Specific Quality-of-Life Questionnaire. Further investigation of the factor structure. | MSQ, the 16-item Migraine-Specific Quality-of-Life Questionnaire (Version 1.0), was developed by Glaxo Wellcome Inc. to assess the effect of migraine and its treatment on patients' health-related quality of life (HR-QOL). The MSQ was hypothesised to measure 3 meaningful dimensions: (i) Role Function-Restrictive; (ii) R... | 0 | 0 |
21,029 | 10,190,654 | The haemodynamic effect of the 5HT1 agonist BMS-180048: a class effect of triptans? | AIMS: To investigate the effects of an intravenous infusion of BMS-180048, a novel 5HT1-like agonist, on the systemic, pulmonary and coronary circulations in patients undergoing diagnostic cardiac catheterisation. METHODS: Ten patients (mean age 55 years (range 41-65)) were studied during diagnostic cardiac catheteris... | 0 | 0 |
21,030 | 10,209,349 | Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine. | This multicentre, randomized, double-blind, placebo-controlled, parallel group dose-ranging study compared the efficacy and tolerability of four doses of sumatriptan nasal spray (2.5, 5, 10 and 20 mg) with a placebo, in the acute treatment of a single migraine attack. In total, 544 patients received the study medicatio... | 0 | 1 |
21,031 | 10,214,534 | A double-blind, randomized, crossover assessment of blood pressure following administration of avitriptan, sumatriptan, or placebo to patients with mild to moderate hypertension. | We examined the effects of avitriptan, a 5-hydroxytryptamine 1-like (5HT1) receptor agonist for the treatment of migraine, in patients with medicated, controlled, mild to moderate hypertension relative to placebo and sumatriptan. The study was randomized, double-blinded, placebo-controlled, and 4-way crossover in desig... | 0 | 1 |
21,032 | 10,214,535 | Effects of zolmitriptan (Zomig) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine. | In this randomized, double-blind, three-period crossover trial, 24 healthy volunteers without migraine received zolmitriptan 5 mg, dexfenfluramine 15 mg or placebo orally. At 2, 6, and 24 h postdose, auditory stimuli of 1000 Hz (nontarget tone) and 2000 Hz (target tone) were randomly and binaurally presented in an acti... | 0 | 0 |
21,033 | 10,214,771 | Naratriptan is effective and well tolerated in the acute treatment of migraine. | null | 0 | 0 |
21,034 | 10,219,932 | Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. | BACKGROUND: Migraine headaches result in significant patient suffering and high costs to managed care organizations and employers. Studies that evaluate patient outcomes and the financial consequences of migraine treatment are important from a clinical and an economic perspective. METHODS: This prospective, observatio... | 0 | 1 |
21,035 | 10,227,648 | Intranasal sumatriptan for the acute treatment of migraine in children. | Sumatriptan is a highly effective treatment for migraine in adults but its efficacy in children has not been determined. Fourteen children with migraine (6.4 to 9.8 years of age; seven girls, six with aura) participated in a randomized double-blind placebo-controlled crossover study to evaluate the efficacy of sumatrip... | 0 | 0 |
21,036 | 10,231,608 | Migraine headaches: nutritional, botanical and other alternative approaches. | Migraine headaches are an increasingly common health problem with a wide range of potential etiological factors. Stress, food allergies, neuroendocrine imbalances and nutritional deficiencies all may contribute to migraine attacks. Many nutritional and botanical therapies aim to reduce migraine incidence by decreasing ... | 0 | 0 |
21,037 | 10,233,200 | Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. | AIMS: The pharmacokinetics and dose proportionality of rizatriptan single oral doses from 2.5 to 15 mg administered as solutions to healthy volunteers were studied. METHODS: In a randomized, crossover study with four periods, twenty-four healthy volunteers (12 males and 12 females) took single oral doses of 2.5, 5, 10... | 0 | 0 |
21,038 | 10,235,690 | Systematic review and guide to selection of selective serotonin reuptake inhibitors. | A meta-analysis of 20 short term comparative studies of 5 selective serotonin reuptake inhibitors (SSRIs; citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline) has shown no difference in efficacy between individual compounds but a slower onset of action of fluoxetine. There were suggestions that fluoxetine ca... | 0 | 0 |
21,039 | 10,329,285 | Intracranial vessels in trigeminal transmitted pain: A PET study. | The underlying principle in interpreting data from positron emission tomography (PET) is that increases and decreases of synaptic activity in the brain are accompanied by equivalent changes in regional blood flow. However, given the relatively low spatial resolution of PET, regional indices of neural activity can be in... | 0 | 0 |
21,040 | 10,345,971 | Maintenance drug therapy of chronic obstructive pulmonary disease. | null | 0 | 0 |
21,041 | 10,358,852 | Focus on primary care diagnosis and management of headache in women. | Women experience unique changes in headache pattern related to changes in their reproductive cycles. Changes predictably occur in association with menarche, menstrual cycling, the use of oral contraceptives, pregnancy, and menopause. These predictable headache changes are linked to changing levels of sex hormones. This... | 0 | 0 |
21,042 | 10,361,566 | Acupuncture for migraine and headache in primary care: a protocol for a pragmatic, randomized trial. | UNLABELLED: This paper presents the protocol for a randomized trial of acupuncture for migraine and headache. SUBJECTS: Four hundred patients with migraine or headache will be recruited from GP practices. INCLUSION CRITERIA: Eighteen to 65 years old, contractable by telephone, onset at least 1 year prior at age less t... | 0 | 0 |
21,043 | 10,362,912 | Issues relating to the assessment of migraine recurrence following triptan therapy. | null | 0 | 0 |
21,044 | 10,376,167 | Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. | To investigate prospectively serious adverse events associated with sumatriptan injection, we studied 12,339 typical migraineurs for up to 12 months each. This study imitated the ordinary clinical use of sumatriptan injection except that: (a) a short, written informed consent was required, (b) there was a centralized, ... | 0 | 1 |
21,045 | 10,376,168 | Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. | BACKGROUND: Migraine attacks are often treated with simple analgesics or with ergotamine-containing preparations alone or in combination with anti-emetics. Although also sometimes used to treat migraine, nonsteroidal anti-inflammatory drugs (NSAIDs) have not been systematically evaluated in controlled clinical trials,... | 0 | 1 |
21,046 | 10,376,171 | Efficacy definitions for migraine studies. | null | 0 | 1 |
21,047 | 10,383,528 | Altered oesophageal motility following the administration of the 5-HT1 agonist, sumatriptan. | BACKGROUND: The 5-HT1 agonist sumatriptan, used in the treatment of migraine, can cause chest pain. AIM: To investigate the effect of a therapeutic dose of sumatriptan (6 mg s.c.) on oesophageal motility. METHODS: In 16 normal healthy subjects aged 19-32 years (9 males), the manometric response of the lower oesophagea... | 0 | 0 |
21,048 | 10,400,409 | Diclofenac-potassium in migraine: a review. | UNLABELLED: The NSAID diclofenac is a potent inhibitor of prostaglandin synthesis and an established antipyretic and analgesic agent. Diclofenac-potassium was developed as an immediate-release tablet with the aim of providing rapid onset of action after oral administration. This formulation has been investigated in th... | 0 | 0 |
21,049 | 10,403,065 | Validation of a migraine work and productivity loss questionnaire for use in migraine studies. | Migraine symptoms and therapy side effects cause significant functional disability that can result in work and productivity losses. Effective, well-tolerated migraine therapy with rapid onset of relief could decrease work and productivity losses. The Migraine Work and Productivity Loss Questionnaire (MWPLQ) evaluates t... | 0 | 1 |
21,050 | 10,403,069 | Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. | Rizatriptan is a potent, highly selective 5HT1B/1D agonist with rapid onset of action for acute treatment of migraine. Rizatriptan wafer is a novel, freeze-dried dosage formulation of rizatriptan which rapidly disintegrates on the tongue, is swallowed with saliva, and may be taken without liquids. The efficacy and tole... | 0 | 1 |
21,051 | 10,405,702 | Treatment of migraine headaches. | Migraine headaches are common and costly. Patients with migraine frequently seek medical attention from primary care physicians. Although effective therapy is available, migraine is underdiagnosed and undertreated. The 3 main forms of management are avoidance of migraine triggers, treatment of the acute attack with med... | 0 | 0 |
21,052 | 10,410,185 | Naratriptan: an alternative for migraine. | OBJECTIVE: To critically evaluate the literature regarding naratriptan's clinical pharmacology, efficacy, safety, and indications. DATA SOURCE: A MEDLINE search was conducted for the period from January 1990 to June 1998. Key words used included naratriptan, triptan, serotonin agonists, migraine, and migraine therapy.... | 0 | 0 |
21,053 | 10,413,073 | Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans. | Naratriptan, an effective antimigraine agent, is a selective 5-hydroxytryptamine (5-HT1 )-receptor agonist with a pharmacologic profile similar to that of sumatriptan. The object of this study was to assess the haemodynamic effects of naratriptan in a clinical model previously applied to sumatriptan. Cardiac haemodynam... | 0 | 1 |
21,054 | 10,417,495 | The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers. | AIMS: The new 5-HT1B/1D agonist rizatriptan (MK-0462) has recently been registered for the treatment of migraine. Its primary route of metabolism is via monoamine oxidase-A (MAO-A). Antidepressants such as the MAO-A inhibitor moclobemide may be used in patients with chronic headache syndromes. Hence, this study aimed ... | 0 | 0 |
21,055 | 10,442,248 | Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. | Drug-induced headache, particularly ergotamine-induced headache, is a common problem in migraine treatment. Some case reports suggest that even the new serotonergic antimigraine drugs such as sumatriptan can lead to overuse and subsequent drug-induced headache. We performed a controlled study to identify the rate of su... | 0 | 1 |
21,056 | 10,448,545 | Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. | Two-hundred-and-seventy-eight patients with acute migraine attacks with or without aura were treated in 17 centers with 1.8 g lysine acetylsalicylate i.v. (Aspisol; = 1 g acetylsalicylic acid), 6 mg sumatriptan s.c. or placebo using a double-blind, double-dummy, randomized, multicenter parallel group study design. Two-... | 0 | 1 |
21,057 | 10,453,967 | Migraine: a comprehensive review of new treatment options. | Headaches are among the most common complaints reported to health care professionals and are classified by the International Headache Society as migraine, tension-type, or cluster, with additional subtypes. Classification and etiology of headache should be determined after thorough review of the patient's history. Once... | 0 | 0 |
21,058 | 10,463,324 | Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors? | RATIONALE: Effective neuroendocrine probes of 5-HT1B and 5-HT1D receptor function may facilitate investigation of the role of these receptor subtypes in the pathophysiology of depression and the mode of action of antidepressant medication. OBJECTIVE: To investigate the neuroendocrine profile of the 5-HT1B/1D receptor ... | 0 | 0 |
21,059 | 10,463,512 | Symptomatic pharmacotherapy of migraine. | This review summarizes data on the effectiveness of various symptomatic migraine pharmacotherapies and makes recommendations for treatment. A wide variety of agents are available for the symptomatic treatment of migraine headache, including over-the-counter analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), com... | 0 | 0 |
End of preview. Expand in Data Studio
cohen-triptans-clean
This dataset was created from the file Triptans-clean.csv in the collection of data files.
Dataset Structure
The dataset contains 671 rows and 6 columns.
Features
recordId: int64PMID: int64title: objectabstract: objectlabels: int64abstract_labels: int64
Source
Original file: Triptans-clean.csv
- Downloads last month
- 4